[vc_row][vc_column][vc_column_text css=”.vc_custom_1655541638859{margin-bottom: 0px !important;}”]With the huge growth in the generic drug market, there is no doubt that generic companies (hey there!) are searching for drugs with a soon-to-be-expired label.
With a new week comes a new list of drug patents expiring. As always, the list includes not just the drug names but also other information like treatment, ingredients, and the disease they cure, which could help them (you) easily choose the drug most profitable to develop a generic version.
Without any delay, here is the list of drugs. Thank us later!
The article has a list of drug patents in 2030. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][mk_fancy_title color=”#2878bf” size=”32″ line_height=”80″ font_weight=”bolder” txt_transform=”uppercase” margin_bottom=”0″ font_family=”none”]Drug Patents Expiring in 2030[/mk_fancy_title][mk_divider margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Tafinlar
Dabrafenib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7994185 | January 20, 2030 |
| US8415345 | January 20, 2030 |
| US8703781 | October 15, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653413919659{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: DABRAFENIB MESYLATE
Treatment: Braf (v600)-mutated Metastatic Melanoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Copiktra
Duvelisib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8193182 | February 13, 2030 |
| USRE46621 | May 17, 2032 |
[/mk_table][vc_column_text css=”.vc_custom_1653414013582{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Secura Bio Inc
Ingredients: DUVELISIB
Treatment: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Follicular Lymphoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Seglentis
Celecoxib/Tramadol[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US10238668 | April 19, 2030 |
| US9012440 | April 19, 2030 |
| US8598152 | April 19, 2030 |
| US10245276 | April 19, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653414098477{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Kowa Pharmaceuticals America Inc
Ingredients: CELECOXIB; TRAMADOL HYDROCHLORIDE
Treatment: Management And Treatment Of Pain[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Veltassa
Patiromer[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8337824 | May 29, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653414167508{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Vifor Pharma Inc
Ingredients: PATIROMER SORBITEX CALCIUM
Treatment: High Blood Potassium[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Olumiant
Baricitinib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8158616 | June 8, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653414219908{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Eli Lilly And Co
Ingredients: BARICITINIB
Treatment: Rheumatoid Arthritis And Covid-19[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Voxzogo
Vosoritide[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8198242 | June 11, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653414274675{margin-bottom: 0px !important;}”]Dosage: Subcutaneous
Company: Biomarin Pharmaceutical Inc
Ingredients: VOSORITIDE
Treatment: Achondroplasia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Apadaz
Acetaminophen/Benzhydrocodone[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9132125 | July 1, 2030 |
| US9549923 | July 1, 2030 |
| US8748413 | July 10, 2030 |
| US8461137 | February 22, 2031 |
[/mk_table][vc_column_text css=”.vc_custom_1653414369736{margin-bottom: 0px !important;}”]Dosage: Subcutaneous
Company: Kvk Tech Inc
Ingredients: ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE
Treatment: Moderate To Severe Pain[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Segluromet
Ertugliflozin-Metformin[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8080580 | July 13, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653414431009{margin-bottom: 0px !important;}”]Dosage: Subcutaneous
Company: Merck Sharp And Dohme Corp
Ingredients: ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE
Treatment: Type 2 Diabetes[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Qinlock
Ripretinib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8188113 | July 27, 2030 |
| US8461179 | June 7, 2032 |
[/mk_table][vc_column_text css=”.vc_custom_1653414509771{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Deciphera Pharmaceuticals Llc
Ingredients: RIPRETINIB
Treatment: Advanced Gastrointestinal Stromal Tumor[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Parsabiv
Etelcalcetide[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9701712 | July 29, 2030 |
| US9278995 | July 29, 2030 |
| US8377880 | July 29, 2030 |
| US8999932 | February 7, 2031 |
[/mk_table][vc_column_text css=”.vc_custom_1653414597607{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Kai Pharmaceuticals Inc
Ingredients: ETELCALCETIDE
Treatment: Secondary Hyperparathyroidism[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Alunbrig
Brigatinib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9012462 | July 31, 2030 |
| US10385078 | November 10, 2035 |
[/mk_table][vc_column_text css=”.vc_custom_1653414706304{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Takeda Pharmaceuticals USA Inc
Ingredients: BRIGATINIB
Treatment: Non Small Cell Lung Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Brexafemme
Ibrexafungerp[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8188085 | August 28, 2030 |
| US10174074 | January 19, 2035 |
| US10927142 | January 19, 2035 |
[/mk_table][vc_column_text css=”.vc_custom_1653414808169{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Scynexis Inc
Ingredients: IBREXAFUNGERP CITRATE
Treatment: Vulvovaginal Candidiasis (VVC)[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row]
[vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Nubeqa
Darolutamide[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8975254 | October 27, 2030 |
| US9657003 | October 27, 2030 |
| US11046713 | October 27, 2030 |
| US10711013 | October 27, 2030 |
| US10383853 | January 28, 2036 |
| US10010530 | January 28, 2036 |
| US11168058 | February 27, 2038 |
[/mk_table][vc_column_text css=”.vc_custom_1653414947362{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Bayer Healthcare Pharmaceuticals Inc
Ingredients: DAROLUTAMIDE
Treatment: Non-metastatic Castration-resistant Prostate Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Harvoni/Hepcinat-LP
Ledipasvir/Sofosbuvir[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8822430 | November 12, 2030 |
| US8088368 | November 12, 2030 |
| US10039779 | July 30, 2034 |
[/mk_table][vc_column_text css=”.vc_custom_1653415029162{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Gilead Sciences Inc
Ingredients: LEDIPASVIR; SOFOSBUVIR
Treatment: Hepatitis C[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Rinvoq
Upadacitinib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE47221 | December 1, 2030 |
| US8962629 | January 15, 2031 |
| US10981923 | October 17, 2036 |
| US9951080 | October 17, 2036 |
| US11186584 | October 17, 2036 |
[/mk_table][vc_column_text css=”.vc_custom_1653415148811{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Abbvie Inc
Ingredients: UPADACITINIB
Treatment: Rheumatoid Arthritis and Psoriatic Arthritis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Nerlynx
Neratinib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7399865 | December 29, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653415214258{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Puma Biotechnology Inc
Ingredients: NERATINIB MALEATE
Treatment: Breast Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row]
